NEW DELHI : Drug sales that fell as India’s first pandemic wave ebbed in the March quarter are expected to rebound in the June quarter, as the havoc from the second wave boosted demand for covid drugs in April and May.Top drugmakers such as Cipla, Dr Reddy’s Laboratories and Zydus Cadila, which have some of the largest portfolios of covid-19 drugs in the country, saw their March quarter sales decline 7-19% from the preceding quarter.“Our India business recorded sales of ₹845 crore with a year-on-year growth of 23% and a sequential decline of 12%.
The sequential decline was driven by reduced demand for covid drugs during this quarter as infections remain low, and seasonal impact in our portfolio," Dr Reddy’s chief executive officer Erez.